GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:
|
|
- Jean Lamb
- 5 years ago
- Views:
Transcription
1 GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus Study No.: (EPI-ROTA ) Title: Case-control study to evaluate the effectiveness of GlaxoSmithKline (GSK) Biologicals live attenuated human rotavirus (HRV) (Rotarix ) against community-acquired rotavirus severe gastroenteritis (RV SGE) among hospitalised children born after 1 October 2006, in Belgium. Rationale: The aim of this study was to assess HRV effectiveness in preventing community-acquired RV SGE among hospitalised infants, in Belgium. The population in this study was limited to children born after 01 October 2006 and at least 14 weeks of age. Baseline data on the proportion of hospital admissions due to RV SGE and co-infections with other organisms were also estimated. Data were also collected from subjects who received Rotateq. Rotateq (Rota): Merck & Co.,Inc. s pentavalent rotavirus Objectives: Primary objective: To estimate the effectiveness of HRV full series (2 doses) in preventing community-acquired RV SGE among hospitalised children born after 01 October 2006 and at least 14 weeks of age. Secondary objectives: To estimate the effectiveness of HRV full series (2 doses) in preventing community-acquired RV SGE by age-groups (3-6 months, 7-12 months, months, > 25 months of age) among hospitalised children born after 01 October 2006 and at least 14 weeks of age. To estimate the effectiveness of HRV when used in typical real-life situations (at least 1 dose i.e. 1 or 2 doses) in preventing community-acquired RV SGE among hospitalised children born after 01 October 2006 and at least 14 weeks of age. To estimate the effectiveness of rotavirus s (HRV or Rota s) when used in typical real-life situations (at least 1 dose i.e. 1, 2 or 3 doses) in preventing community-acquired RV SGE among hospitalised children born after 01 October 2006 and at least 14 weeks of age. In order to estimate the overall burden of disease due to RV SGE, co-infection with other organisms and distribution of RV type in the study subjects during the study period, the following secondary study objectives were also considered: To estimate the proportion of RV SGE admissions in children born after 01 October 2006 and at least 14 weeks of age. To estimate the proportion of RV SGE hospitalisations co-infected with other organisms (Astrovirus, Norovirus, Adenovirus) among children born after 01 October 2006 and at least 14 weeks of age. To determine the distribution of RV SGE hospital admissions by the age of the child, month of year and RV type, among hospitalised children born after 01 October 2006 and at least 14 weeks of age. Indication: Prevention of community-acquired RV SGE in infants aged at least 14 weeks. Study Investigators/Centres: GSK conducted study in 39 centres across Belgium. Only 32 of the centres enrolled subjects. Research Methods: Data Source: Parents/guardians interview, review of medical records and cards, stool sampling Study Design: Hospital-based, multi-centre, matched (by hospital and age), case-control study. Study Population: - Enrolled cases included all children born after 01 October 2006, at least 14 weeks of age (minimum age at which both doses of HRV should have been administered along with 2 weeks for the development of immunity), and hospitalised for SGE at the study hospitals during the designated study period of at least one year. - Probable cases included those children who were born after 01 October 2006, at least 14 weeks of age, hospitalised for SGE in the study hospitals and whose stool samples had been tested positive for RV by a rapid test at the bedside or hospital laboratory. - Confirmed cases included those children who were born after 01 October 2006, at least 14 weeks of age, hospitalised for SGE in the study hospitals and whose stool samples had been tested positive for RV by polymerase chain reaction (PCR) at the GSK designated laboratory. For each probable case, one control hospitalised or visiting the hospital outpatient clinic for non-ge causes in the same study hospital, during the same time period as the case, was included after matching by age (up to a maximum of ± 6 weeks from the date of birth of the case). Informed consent was sought from parents/guardians of all eligible cases. Study Exposures, Outcomes: The study groups were as follows: - Cases Group: Subjects born after 01 October 2006, at least 14 weeks of age and hospitalised for SGE (see the definitions of enrolled, probable and confirmed cases in the Study Population section). - Controls Group: Subjects matched by age with the cases, hospitalised or visiting the hospital outpatient clinic for
2 non-ge causes in the same study hospital, during the same time period. Primary outcome Occurrence of PCR-confirmed RV SGE (> 14 days after receipt of ) in children fully vaccinated with HRV or in unvaccinated children. Secondary outcomes Occurrence of PCR-confirmed RV SGE (> 14 days after receipt of ) in children who received one or two doses of HRV or in unvaccinated children. Occurrence of PCR-confirmed RV SGE (>14 days after receipt of ) in children who received at least one dose of HRV or Rota s or in unvaccinated children. Following outcomes needed to estimate the burden of RV SGE, co-infection with other organisms and RV strain distribution in study subjects: Occurrence of SGE due to RV among children born after 01 October 2006, at least 14 weeks of age and admitted to hospital. Occurrence of co-infections with other organisms (Astrovirus, Norovirus and Adenovirus) among children born after 1 October 2006, at least 14 weeks of age and hospitalized with PCR-confirmed RV SGE. Occurrence of PCR-confirmed RV SGE by age and month of year, among children born after 01 October 2006, at least 14 weeks of age and admitted to the hospital. Occurrence of RV types among hospitalized PCR-confirmed RV SGE children born after 01 October 2006 and at least 14 weeks of age. Data Analysis Methods: Analyses were performed on the Total screened cases cohort, the Total enrolled cohort, the According-To-Protocol (ATP) enrolled cohort and the ATP confirmed cohort. - The Total screened cases cohort included all children born after 01 October 2006 and at least 14 weeks of age, who were admitted to the hospital for symptoms of SGE. - The Total enrolled cohort included all subjects (cases and controls) enrolled in the study. - The ATP enrolled cohort included all valid enrolled cases and controls (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol). Cases may not have had any control in this cohort (e.g. for not probable cases, no controls were looked for; controls may not have been found etc). However, controls with no eligible cases were eliminated from this cohort. - The ATP confirmed cohort included all valid confirmed cases (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) and their matched controls. Confirmed cases without matched controls were eliminated from this cohort. Vaccine effectiveness () analysis Vaccine effectiveness was calculated as 1 minus the matched odds ratio multiplied by 100%. Matched odds ratios for were calculated as the hazard ratio by using the conditional logistic regression, with associated p-values and 95% confidence intervals. The was evaluated in the following circumstances: 1. Fully vaccinated with HRV against unvaccinated (overall and by age classes). 2. Fully or partially vaccinated with HRV against unvaccinated. 3. Fully or partially vaccinated with HRV or Rota s against unvaccinated. All s were estimated on one hand with pairs for which the case and control(s) had a validated source of history and on the other hand including all pairs (whatever the source of ). Note: Only confirmed cases and their respective controls (if at least one valid control) were taken. Finally, a sensitivity analysis was conducted by including subjects whose status was other or for s 1 or 2 and for 3. This status could be determined with assumptions that these subjects were and were not vaccinated (Sensitivity +: cases and controls were assumed respectively ; Sensitivity -: cases and controls were assumed respectively ). Burden of disease analysis The proportion of SGE hospitalisations attributable to RV was computed with 95% confidence interval (CI) and was also cross-tabulated with co-infection as the proportion of SGE hospitalisations attributable to Rapid test positive SGE, the proportion of Rapid test positive SGE hospitalisations attributable to PCR positive RV and the proportion of PCR positive RV SGE hospitalisations attributable to co-infected RV. The distribution of cases by year and month of hospitalisations and the distribution of rotavirus genotypes by age groups were also tabulated. Limitations: Not applicable
3 Study Results: Demographics/Baseline Characteristics Cases Group Controls Group N (Total enrolled cohort ) Females:Males* 143: :188 Mean Age, Months (SD) 13.0 (7.26) 16.7 (7.97) *Note: Gender was missing for 246 subjects in the Cases Group and 12 subjects in the Controls Group. Primary outcome: Effectiveness of HRV full series (ATP confirmed cohort) Number of Cases Number of Controls 95%CI Fully HRV Fully HRV LL UL All sources Validated Sensitivity Number of Cases Number of Controls Fully HRV Other or Fully HRV Other or Sens.+ Sens.- All sources Validated Note: Fully HRV means 2 doses of HRV All sources for Sensitivity: rotavirus vaccinated status of the case and the matched control are fully HRV vaccinated, not vaccinated, or other. All sources for : rotavirus vaccinated status of the case and the matched control are fully HRV vaccinated or not vaccinated. Validated: Only validated sources, meaning that in addition, sources of the case and of the matched control must be validated. Sens.+ = Sensitivity +: cases and controls with other or rotavirus status are assumed respectively Sens. - = Sensitivity -: cases and controls with other or rotavirus status are assumed respectively Secondary outcome: Effectiveness of HRV full series by age group of the case (ATP confirmed cohort) Number of Cases Number of Controls 95%CI Sensitivity Age Fully HRV Fully HRV LL UL Sens. + Sens. - (months) All sources Validated = Between 3 and 6 months of age (6 not included) 6-11 = Between 6 and 12 months of age (12 not included) = Between 12 and 24 months of age (24 not included) 24+ = More than 24 months of age (24 included) Note: Fully HRV means 2 doses of HRV All sources for Sensitivity: rotavirus vaccinated status of the case and the matched control are fully HRV, not vaccinated, or other. All sources for : rotavirus vaccinated status of the case and the matched control are fully HRV vaccinated or not vaccinated. Validated: Only validated sources meaning that in addition, sources of the case and of the matched control must be validated.
4 Sens.+ = Sensitivity +: cases and controls with other or rotavirus status are assumed respectively Sens. - = Sensitivity -: cases and controls with other or rotavirus status are assumed respectively Note: For 3-5 and 24+ age classes, not enough cases and controls were enrolled as per the inclusion/ exclusion criteria. Secondary outcome: Effectiveness of HRV partial or full (intention to vaccinate analysis) series (ATP confirmed cohort) Number of Cases Number of Controls 95%CI HRV HRV All sources Validated Sensitivity Partial or full HRV Number of Cases Other or Partial or full HRV Number of Controls Other or LL UL Sens. + Sens. - All sources Validated Note: Partial/full HRV means at least 1 dose of HRV. All sources for Sensitivity: rotavirus vaccinated status of the case and the matched control are fully or partially HRV vaccinated, not vaccinated, or other. All sources for : rotavirus vaccinated status of the case and the matched control are fully or partially HRV vaccinated or not vaccinated. Validated: Only validated sources meaning that in addition, sources of the case and of the matched control must be validated. Sens.+ = Sensitivity +: cases and controls with other or rotavirus status are assumed respectively Sens. - = Sensitivity -: cases and controls with other or rotavirus status are assumed respectively Secondary outcome: Effectiveness of rotavirus s partial or full series (ATP confirmed cohort) Number of Cases Number of Controls 95%CI All sources Validated Sensitivity Partial or full Number of Cases Other or Number of Controls Other or LL UL Sens. + Sens. - All sources Validated Note: Partial/full vaccinated means at least 1 dose of rotavirus. All sources for Sensitivity: all matched case and control. All sources for : case and matched control with at least one of both rotavirus status set to or other are not part from the analysis. Validated: Only validated sources meaning that in addition, sources of the case and of the matched control must be validated. Sens.+ = Sensitivity +: cases and controls with other or rotavirus status are assumed respectively
5 Sens. - = Sensitivity -: cases and controls with other or rotavirus status are assumed respectively Secondary outcome: Proportion of SGE hospitalisations attributable to Rapid test positive SGE (Total screened cases cohort (aggregated logbook)) Number of RV SGE Number of SGE hosp. Proportion LL UL hosp. with Rapid test Note: Number of SGE hosp. and RV SGE are computed from the aggregated logbook. No consistency checks have been done between the aggregated logbook and the initial logbook. LL, UL = 95% Lower and Upper exact confidence limits Secondary outcome: Proportion of Rapid test positive SGE hospitalisations attributable to PCR+ RV (ATP enrolled cohort) Number of PCR+ RV SGE hosp. Number of RV SGE hosp. with Rapid test Proportion LL UL Sens + Sens LL, UL = 95% Lower and Upper exact confidence limits Sens + = Sensitivity +: cases with PCR result are assumed RV SGE Sens - = Sensitivity -: cases with PCR result are assumed SGE not RV Secondary outcome: Proportion of PCR+ RV SGE hospitalisations attributable to co-infected RV (ATP enrolled cohort) Co-infection Number of SGE hosp. due to RV / RV coinfection Number of PCR+ RV SGE hosp. Proportion None (only RV) Astrovirus Norovirus Adenovirus Any Co-infections Astro/Noro Astro/Adeno Noro/Adeno Note: The sensitivity analysis was not performed because no records were observed for co-infection. Note: Number of SGE hosp. and RV / RV co-infection SGE are computed from the cases in the ATP enrolled cohort with a PCR positive result and from the cases in the ATP with a PCR positive result and possible co-infection, respectively. Secondary outcome: Distribution of cases by year and month of hospitalisations (ATP confirmed cohort) Total N = 215 Characteristics Categories n % Year and month of hospitalisation LL UL
6 N = number of screening cases n = number of screening cases in a given category % = n / Number of screening cases with available results x 100 Secondary outcome: Distribution of RV genotypes for confirmed cases overall and by age group (ATP confirmed cohort) 3-5 N = N = N = N = 21 Categories n % LL UL n % LL UL n % LL UL n % LL UL G-other P[14] G12P[6] G12P[8] G1P[8] G2P[4] G3P[8] G4P[8] G9P[8] MIMI MIP[8] Total N = 215 Categories n % LL UL G-other P[14] G12P[6] G12P[8] G1P[8] G2P[4] G3P[8] G4P[8] G9P[8] MIMI MIP[8] = Between 3 and 6 months of age (6 not included) 6-11 = Between 6 and 12 months of age (12 not included) = Between 12 and 24 months of age (24 not included) 24+ = More than 24 months of age (24 included) N = number of confirmed RV cases n = number of confirmed RV cases with the specified genotype % = n / Number of confirmed RV cases with available results x 100 LL, UL for percentage = Exact 95% Lower and Upper confidence limits MI=mixed infection Conclusion: Vaccine effectiveness of HRV full series (2 doses) in preventing community-acquired RV SGE among hospitalised children born after 1 October 2006 and at least 14 weeks of age was estimated at 90.24%. Date updated: 05-August-2013
GSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design
GSK Medicine: Rotarix (HRV1): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus vaccine Study No.: 114910 (EPI-ROTA-025 VE AU DB) Title: A study on the impact of rotavirus vaccination
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEffectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases
TECHNICAL DOCUMENT Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Effectiveness
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCorrelates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations
Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,
More informationRotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April
Rotavirus serotype surveillance: Results and experiences in Tanzania Adolfine Hokororo KPA Vaccinology Symposium- 29 th April 2016 1 outline 1. Introduction-burden of RVGE 2. goals of RVGE sentinel surveillance
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationViral Agents of Paediatric Gastroenteritis
Viral Agents of Paediatric Gastroenteritis Dr Carl Kirkwood -------------------- Enteric Virus Research Group Murdoch Childrens Research Institute Royal Children s Hospital Victoria. WHO Collaborating
More informationVaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV
Supplemental Digital Content 1. Methodology Inclusion and exclusion criteria Eligible participants were infants between and including 6 10 weeks of age at the time of the first vaccination, who were free
More informationRotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types
Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development
More informationStudy No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:
GSK Medicine: Not applicable Study No.: 113564 (EPI-HAV-003 BOD MX) Title: Sero-prevalence of Hepatitis A, Varicella-Zoster virus, Cytomegalovirus, Herpes Simplex and Bordetella pertussis in Mexico. Rationale:
More informationNorthwestern Health Unit
Northwestern Health Unit www.nwhu.on.ca 210 First Street North Kenora Ontario P9N 2K4 1-800-830-5978 July 26, 2018 Re: Ontario Rotavirus Immunization Program - Transitioning to RotaTeq (Rot-5) pentavalent
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert
GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT Rotarix TM 1 WHO Package insert GlaxoSmithKline Biologicals Rotarix Method of administration Rotarix is for oral use only. ROTARIX SHOULD UNDER NO
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHow to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries?
How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries? Elmira Flem Department of Vaccines Norwegian Institute of Public Health Nordic Vaccine Meeting April
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFor the additional vaccination phase
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPrevention of Rotavirus Infections. Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti
Prevention of Rotavirus Infections Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti Worldwide, Rotavirus Accounted for ~215,000 Childhood Deaths Annually 1 (2000-2013) In children less than 5 years of age:
More informationBurden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination
Carlo GIAQUINTO Pediatrics Department University of Padova, Italy Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination Preliminary results 7th International Rotavirus
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationsubjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationvaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLong-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnalysis of immunogenicity
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBangladesh: How to move from data to implementation. K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b
Bangladesh: How to move from data to implementation K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b Rotavirus in Bangladesh Estimated 2.4 million cases of rotavirus diarrhoea annually in
More informationUpdate on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014
Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating
More informationEfficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish Extension Study
Eur J Pediatr (2010) 169:1379 1386 DOI 10.1007/s00431-010-1242-3 ORIGINAL PAPER Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish Extension Study
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationVaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA
TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children
More informationRotavirus: WHO Global Recommendations, Policy, and Surveillance
Rotavirus: WHO Global Recommendations, Policy, and Surveillance 9 th International Rotavirus Symposium 2 August 2010 Mary Agócs, MD, MSc Department of Immunization, Vaccines & Biologicals From 1999 2009:
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPopulation effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies
Hungerford et al BMC Infectious Diseases (2017) 17:569 DOI 101186/s12879-017-2613-4 RESEARCH ARTICLE Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and
More informationAppendix I: Patient-relevant outcomes, literature search, inclusion and exclusion criteria, flow charts
Appendices I-V Koch J, Wiese-Posselt M, Remschmidt C, Wichmann O, Bertelsmann H, Garbe E, Hengel H, Meerpohl JJ, Mas Marques A, Oppermann H, Hummers-Pradier E, von Kries R, Mertens T. Background paper
More informationDESCRIPTION OF STUDIES AND RISK OF BIAS ASSESSMENT FOR RCTS
DESCRIPTION OF STUDIES AND RISK OF BIAS ASSESSMENT FOR RCTS ROTAVIRUS VACCINES SCHEDULES: A SYSTEMATIC REVIEW OF SAFETY AND EFFICACY FROM RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES OF CHILDHOOD
More informationStudy No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMenC. MenW MenY
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationA Human Rotavirus Vaccine
7th International Rotavirus Symposium Lisbon, Portugal, 12-13 June 2006 A Human Rotavirus Vaccine Dr. Béatrice De Vos GlaxoSmithKline Biologicals Rixensart, Belgium Rotarix is a trade mark of the GlaxoSmithKline
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWhat s New In Pediatric Vaccines? and Addressing Vaccine Hesitancy
What s New In Pediatric Vaccines? and Addressing Vaccine Hesitancy Kathryn M. Edwards MD Sarah H. Sell and Cornelius Vanderbilt Chair Professor of Pediatrics Vanderbilt University Medical Center Disclosures
More informationRotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
More informationDecision-making by the Advisory Committee on Immunization Practices
Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCountry spotlight: Fiji
Country spotlight: Fiji Fiona Russell, Centre for International Child Health, WHO Collaborating Centre for Research & Training in Child & Neonatal Health, Dept of Paediatrics, The University of Melbourne
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationFor the use only of registered medical practitioners or a hospital or a laboratory ROTARIX. Rotavirus Vaccine (Live Attenuated, Oral) IP
For the use only of registered medical practitioners or a hospital or a laboratory ROTARIX Rotavirus Vaccine (Live Attenuated, Oral) IP 1. NAME OF THE MEDICINAL PRODUCT Rotavirus Vaccine (Live Attenuated,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRotarix TM. Rotavirus vaccine. 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID50 PHARMACEUTICAL FORM Oral suspension.
More informationA rotavirus immunisation programme was introduced into the routine childhood immunisation programme from 1 July 2013 for infants aged 2 and 3 months.
A rotavirus immunisation programme was introduced into the routine childhood immunisation programme from 1 July 2013 for infants aged 2 and 3 months. Rotavirus is a very common and potentially serious
More informationDr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine
Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases; Medical Research Council: Respiratory and
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationVIRAL GASTROENTERITIS
VIRAL GASTROENTERITIS (GI & N Block, Microbiology : 2016) By: Dr.Malak M. El-Hazmi OBJECTIVES Ø VIRAL GASTROENTERITIS (VGE) n Etiology of VGE n Epidemiology n Clinical Features n Lab diagnosis n Treatment
More informationD-QIV_LP 6-35m Group: Subjects aged 6-35 months received 1 or 2 doses of D-QIV_IP vaccine depending on vaccine-priming
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationROTAVIRUS VACCINES FOR AUSTRALIAN CHILDREN: INFORMATION FOR GPS AND IMMUNISATION PROVIDERS
ROTAVIRUS VACCINES FOR AUSTRALIAN CHILDREN: INFORMATION FOR GPS AND IMMUNISATION PROVIDERS Summary Rotavirus is the most common cause of severe gastroenteritis in infants and young children, accounting
More informationVaccination with RotaTeq. Questions & Answers for Immunization Providers
Vaccination with RotaTeq Questions & Answers for Immunization Providers Office of the Chief Medical Officer of Health Communicable Disease Control Branch June 2018 1. Why is a rotavirus vaccine program
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationApproaches to Assessing Intussusception Risk in Developing Countries
Approaches to Assessing Intussusception Risk in Developing Countries Jacqueline Tate Centers for Disease Control and Prevention Atlanta, GA, USA National Center for Immunization & Respiratory Diseases
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSynopsis of study HBV-314 BST 280 (108988)
Synopsis of study HBV-314 BST 280 (108988) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More informationRotavirus. Rotavirus. Vaccine-Preventable Diseases WHO Vaccine-Preventable Diseases Surveillance Standards. Surveillance Standards
Last updated: September 5, 2018 Vaccine-Preventable Diseases Surveillance Standards 1 DISEASE AND VACCINE CHARACTERISTICS, a member of the reovirus family, causes watery diarrhoea, vomiting and severe
More informationDoes Rota Vaccine Reduce Attacks of Acute Gastroenteritis among Children Under 15 Months of Age?
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1178-1184 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.142
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHealth benefits versus intussusception risk of rotavirus vaccination in Australia
Health benefits versus intussusception risk of rotavirus vaccination in Australia Julie Bines 1 On behalf of co-authors: John Carlin 1, Kristine Macartney 2, Katherine Lee 1, Helen Quinn 2, Jim Buttery
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rotarix powder and solvent for oral suspension Rotavirus vaccine, live 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationInvestigation of a Neisseria meningitidis Serogroup A Case in the Meningitis Belt. January 2017
January 2017 Investigation of a Neisseria meningitidis Serogroup A Case in the Meningitis Belt Introduction Since the progressive introduction of meningococcal serogroup A conjugate vaccine (MACV) in the
More informationFecal shedding of rotavirus vaccine in premature babies in the neonatal unit
Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit Dr. Manish Sadarangani Director, Vaccine Evaluation Center, BC Children s Hospital Research Institute Assistant Professor, Division
More informationSynopsis for study HAV-112 EXT M210 (110678)
Synopsis for study HAV-112 EXT M210 (110678) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rotarix powder and solvent for oral suspension Rotavirus vaccine, live 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationEffectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus
Effectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus Anna Lena Lopez, MD, MPH Director, Institute of Child Health and Human Development,
More informationRotavirus Vaccine Program in British Columbia Information for Health Care Providers Date of Issue: February 2012
Rotavirus Vaccine Program in British Columbia Information for Health Care Providers Date of Issue: February 2012 Program background, rationale and eligibility: 1. Why is a rotavirus vaccine program being
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationDirector of Public Health Board Paper No. 13/13
Greater Glasgow and Clyde NHS Board Director of Public Health Board Paper No. 13/13 Report of the Director of Public Health : Major Development to Immunisation Programmes in Scotland Implications for NHSGGC
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationVariation in Rotavirus Vaccine Coverage by Provider Location and Subsequent Disease Burden
Variation in Rotavirus Vaccine Coverage by Provider Location and Subsequent Disease Burden Leila C. Sahni, MPH a, Jacqueline E. Tate, PhD b, Daniel C. Payne, PhD, MSPH b, Umesh D. Parashar, MBBS, MPH b,
More informationLessons from Rotavirus Vaccine Implementation in the U.S.
Lessons from Rotavirus Vaccine Implementation in the U.S. Jeff Duchin, MD Chief, Communicable Disease Epidemiology & Immunization Section Public Health - Seattle & King County Professor in Medicine, Division
More informationUpdates on Rotasiil development
Updates on Rotasiil development 13 th International Rotavirus Symposium Minsk, Belarus 30 August 2018 Dr Sajjad Desai MD Serum Institute of India Pvt Limited, Pune Rotasiil Bovine-human reassortant strains
More information